Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

TRICAV-II Pivotal : système de valve biCAVal TRIcvalve pour la régurgitation tricuspide sévère. (TRICAV-II)

12 novembre 2026 mis à jour par: P+F Products + Features USA Inc.

Un essai clinique prospectif, multicentrique et randomisé du système de valve bicave transcathéter TricValve chez des sujets présentant une régurgitation tricuspide (TR) sévère.

Pivotal trial to evaluate the safety and effectiveness of the P&F TricValve® Transcatheter Bicaval Valve System.

Aperçu de l'étude

Description détaillée

The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the TricValve System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with severe tricuspid regurgitation and unsuitable for approved transcatheter therapies. Subjects will be followed at discharge, 1 month, 30 days, 3 months, 6 months 12 months, and annually up to 5 years.

Type d'étude

Interventionnel

Inscription (Estimé)

780

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Alabama
      • Birmingham, Alabama, États-Unis, 35233
        • University of Alabama
    • Arizona
      • Phoenix, Arizona, États-Unis, 85013
        • St. Joseph's Hospital and Medical Center
    • California
      • Sacramento, California, États-Unis, 95817
        • UC Davis Health
      • San Diego, California, États-Unis, 92037
        • Scripps Memorial Hospital La Jolla
      • San Francisco, California, États-Unis, 94143
        • UCSF
      • San Jose, California, États-Unis, 94118
        • Kaiser Permanente
        • Chercheur principal:
          • Andrew Rassi, MD
        • Contact:
    • District of Columbia
      • Washington D.C., District of Columbia, États-Unis, 20010
        • MedStar Washington Hospital Center (MWHC)
        • Contact:
          • Erin Collins
        • Chercheur principal:
          • Toby Rogers, MD
    • Florida
      • Delray Beach, Florida, États-Unis, 33484
        • Delray Medical Center
      • Largo, Florida, États-Unis, 33770
      • Tampa, Florida, États-Unis, 33606
        • Tampa General Hospital
    • Illinois
      • Glenview, Illinois, États-Unis, 60026
        • Endeavor Health
    • Indiana
      • Indianapolis, Indiana, États-Unis, 46260
        • Ascension Medical Group St. Vincent The Heart Center of Indiana
    • Kansas
      • Kansas City, Kansas, États-Unis, 66103
        • University of Kansas Medical Center
    • Louisiana
      • Houma, Louisiana, États-Unis, 70360
        • Cardiovascular Institute of the South
        • Chercheur principal:
          • Peter Fail, MD
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, États-Unis, 02114
        • Massachusetts General Hospital
      • Burlington, Massachusetts, États-Unis, 01805
        • Lahey Hospital & Medical Center
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55407
        • Minneapolis Heart Institute Foundation
    • Missouri
      • Kansas City, Missouri, États-Unis, 64111
        • Saint Luke's Mid America Heart Institute
      • St Louis, Missouri, États-Unis, 63110
        • Washington University of St Louis
    • New Jersey
      • Hackensack, New Jersey, États-Unis, 07601
        • Hackensack University Medical Center
    • New York
      • Manhasset, New York, États-Unis, 11030
        • Northwell Hospital
      • The Bronx, New York, États-Unis, 10467
        • Montefiore Medical Center
    • Ohio
      • Cleveland, Ohio, États-Unis, 44106
        • Cleveland Clinic
        • Chercheur principal:
          • Rishi Puri, MD
      • Columbus, Ohio, États-Unis, 43214
        • Riverside Methodist Hospital
    • Oregon
      • Portland, Oregon, États-Unis, 97239
        • Oregon Health
        • Chercheur principal:
          • Firas Zahr, MD
        • Contact:
          • Halie Ropp
          • Numéro de téléphone: 503-494-1147
          • E-mail: ropph@ohsu.edu
    • South Carolina
      • Charleston, South Carolina, États-Unis, 29425
        • MUSC
    • Texas
      • Houston, Texas, États-Unis, 77030
        • Houston Methodist
      • Houston, Texas, États-Unis, 77030
        • University of Texas (Memorial Hermann)
      • Plano, Texas, États-Unis, 75093
        • Baylor Scott & White Medical
    • Utah
      • Murray, Utah, États-Unis, 84107
        • Intermountain Heart Institute - Intermountain Medical Center
        • Chercheur principal:
          • Brian Whisenant, MD
        • Contact:
    • Virginia
      • Charlottesville, Virginia, États-Unis, 22903
        • UVA School of Medicine
      • Norfolk, Virginia, États-Unis, 23507
        • Sentara Healthcare
      • Roanoke, Virginia, États-Unis, 24014
        • Carilion Clinic

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 85 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Eligibility Criteria for Randomized Cohort:

Inclusion Criteria:

  1. Age between 18 years and 85 years old, at the time of signing the informed consent.
  2. Severe tricuspid regurgitation (TR) and Caval Reflux (CR), as determined by the qualifying transthoracic echocardiogram (TTE) confirmed by an echocardiography Core Lab. TVARC criteria will be used for the definition of TR severity.
  3. NYHA Class II-III-IVa (not on inotropes, IABP or LVAD) or heart failure (HF) admission in the past 6 months.
  4. Adequately treated with optimal medical therapy (OMT) for heart failure per the local Heart Team at the time of TR assessment for eligibility (TTE). OMT includes stable oral diuretic medications.
  5. High risk for open surgery and is appropriate for transcatheter tricuspid therapies according to the local heart team.
  6. Patient is unsuitable for approved transcatheter therapies and is eligible for the TricValve procedure, based on review of screening/baseline data and imaging core lab measurements by Central Screening Committee.
  7. For females of childbearing potential, negative pregnancy test.
  8. Capable and willing to provide signed informed consent

Exclusion Criteria:

CONCOMITANT PROCEDURES

  1. Patient had a recent MI, stroke, or cardiovascular accident; underwent coronary artery bypass graft surgery, had a percutaneous coronary intervention or other major cardiovascular surgery within 90 days prior to TricValve implantation.

  2. Patient requires another planned major cardiac procedure, including left-sided transcatheter intervention or surgery (e.g. severe aortic stenosis, severe mitral regurgitation), coronary artery bypass or PCI or pulmonary valve correction.

    CARDIOVASCULAR CONDITIONS

  3. LVEF ≤ 30% on echocardiography.

  4. Evidence of intracardiac, inferior vena cava (IVC), or femoral venous mass, thrombus or vegetation.

  5. Severe right ventricular dysfunction.

  6. Cardiac amyloidosis.

  7. Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or right heart catheterization.

  8. Lower extremity venous thrombosis and/or the presence of an IVC filter at the time of or 6 months prior to the TricValve procedure.

  9. Hemodynamically significant pericardial effusion.

  10. Hemodynamic instability, cardiogenic shock, inotropic support, intra-aortic balloon pump or acute heart failure within 30 days prior to the TricValve procedure.

  11. Patient with refractory heart failure requiring advanced intervention (i.e. left ventricular assist device, transplantation) (ACC/ AHA/ ESC/ EACTS Stage D heart failure).

  12. Presence of significant congenital or acquired heart disease such as RV dysplasia, arrhythmogenic RV or other conditions that could interfere with the TricValve procedure.

    ALLERGIES / INTOLERANCE

  13. Any known allergy or hypersensitivity to nitinol, bovine tissue, or contrast media that cannot be adequately treated with pre-medication.

  14. Unable to tolerate anticoagulation/antiplatelet therapy

    COMORBIDITIES

  15. Any known life-threatening condition with an estimated life span of less than 12 months.

  16. Platelet count < 75,000/mm3

  17. Child-Pugh Severity Class C (10-15 points).

  18. Severe renal insufficiency with estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2 or requiring chronic renal replacement therapy at the time of enrollment.

  19. Endocarditis or active/ongoing infection requiring antibiotics.

  20. Unable to walk at least 100 meters in a 6-minute walk test.

  21. Known bleeding or clotting disorders or patient refuses blood transfusion.

  22. Active gastrointestinal (GI) bleeding within 3 months of TricValve procedure.

  23. Prior Malignancy: this study excludes participants at material risk of near-term cancer-related morbidity/mortality that could confound 12-month outcomes. This study allows the inclusion of fully treated, remote malignancies with documented No Evidence of Disease (NED)" criteria

    a. History of any malignancy within 5 years prior to randomization or any active malignancy, except: i. Adequately treated non-melanoma skin cancer (basal or squamous cell) with no evidence of disease, or ii. Carcinoma in situ (e.g., cervical, breast DCIS) treated with curative intent and no evidence of disease.

    b. Participants with a prior malignancy diagnosed >5 years before randomization are eligible if they meet all of the "No Evidence of Disease (NED)" criteria as specified below: i. No signs/symptoms of cancer on history and physical exam per standard of care; ii. No radiologic evidence of disease on surveillance imaging if such imaging is routinely indicated for that tumor type (not protocol-mandated); iii. Tumor markers (if applicable for that cancer) not suggestive of recurrence (e.g., stable/undetectable within site's lab reference and oncologist's judgment); iv. No active anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, targeted therapy, radiotherapy) and none planned; v. Treating oncologist's attestation (or primary physician if oncology follow-up is complete) that the participant is disease-free and appropriate for participation.

    GENERAL EXCLUSIONS

  24. Use or participation in other investigational device or drug study in which the patient has not reached a primary endpoint to treat cardiovascular conditions related to the outcomes of the current study.

  25. Any other condition that would preclude the ability to meet study requirements in the opinion of the investigator.

  26. Psychiatric/behavioral issues or other medical or social conditions that preclude valid consent and follow-up

  27. Pregnant or breastfeeding subjects and those who plan pregnancy during the clinical investigation follow-up period.

Eligibility Criteria for Single Arm Cohort:

Inclusion Criteria:

  1. Age > 85 years.
  2. NYHA Class III-IV, on intravenous inotropes, IABP or LVAD.
  3. LVEF ≤ 30% on echocardiography.
  4. Severe RV dysfunction.
  5. Severe pulmonary hypertension (PH), defined as Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or mean Pulmonary Artery Pressure (mPAP >35) by right heart catheterization.
  6. Renal insufficiency: eGFR between 25 and 30 mL/min/ 1.73 m² or on chronic renal replacement therapy.
  7. Patient unable to walk a minimum distance of 100 mt during 6 minute walk test.
  8. Prior malignancy not meeting the requirements applied for the Randomized Cohort, specified in Exclusion Criterion #23.
  9. Comorbidities precluding inclusion in the Randomized Cohort (exclusion criteria #15 to #24).

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: TricValve System + Optimal medical therapy (OMT)

Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy (OMT) in patients with caval reflux and tricuspid regurgitation.

• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy

Autres noms:
  • Heterotopic caval valve implantation (CAVI)

Optimal medical therapy

Autres noms:
  • OMT
Comparateur actif: Optimal medical therapy (OMT) Alone

OMT alone in patients with caval reflux and tricuspid regurgitation

Optimal medical therapy

Autres noms:
  • OMT
Expérimental: TricValve Single Arm Registry

Single-Arm Registry for Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with OMT in patients with caval reflux and tricuspid regurgitation who are not eligible for randomization

• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy

Autres noms:
  • Heterotopic caval valve implantation (CAVI)

Optimal medical therapy

Autres noms:
  • OMT

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Randomized Cohort: Caval Reflux (CR) grade reduction
Délai: 6 months

Reduction in Caval Reflux (CR) assessed by the echocardiography core laboratory. The CR will be assessed using the 3-grade scale: Grade 1 (no reflux, reflux extending for less than 1 cm below the diaphragm), Grade 2 ( reflux extending for less than 3 cm), Grade 3 (reflux of 3 cm or more). Lower grades of CR are better.

6 months
Randomized Cohort: Hierarchical composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement
Délai: 6 months

Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm.

6 months
Randomized Cohort: Rate of Major Adverse Events (MAE)
Délai: 30 days

Rate of Major Adverse Events (MAE) in experimental arm (TricValve + OMT)

30 days
Randomized Cohort: Hierarchical composite endpoint: all-cause mortality, RVAD implantation or heart transplant, tricuspid valve surgery or percutaneous tricuspid intervention, heart failure hospitalizations, KCCQ improvement, NYHA functional class improv
Délai: 1 year

Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm.

1 year
Registry Cohort: Rate of Major Adverse Events (MAE)
Délai: 30 days

Rate of Major Adverse Events (MAE) in single arm registry

30 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Randomized Cohort: Percentage of Device- and/or Procedure-related MAEs
Délai: 1 year

Rate of Major Adverse Events

1 year
Randomized Cohort: All-Cause mortality and Cardiovascular Mortality
Délai: 6 months and 1 year

Number of deaths from any cause as well as cardiovascular events

6 months and 1 year
Randomized Cohort: Heart Failure Hospitalizations (HFH)
Délai: 6 months and 1 year

Number of Heart Failure Hospitalizations and worsening HF events without hospitilization

6 months and 1 year
Randomized Cohort: RVAD Implantation or Heart Transplant
Délai: 6 months and 1 year

Number of patients requiring RVAD Implantation or Heart Transplant

6 months and 1 year
Randomized Cohort: Atrial Fibrillation
Délai: 1 year

New onset of atrial fibrillation

1 year
Randomized Cohort: Quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) .
Délai: 6 months and 1 year

Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL)

6 months and 1 year
Randomized Cohort: Changes in symptom status New York Heart Association (NYHA class)
Délai: 6 months and 1 year

Reduction of at least 1 class from baseline. The NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

6 months and 1 year
Randomized Cohort: Changes in functional capacity (6-minute walk test, 6MWT).
Délai: 6 months and 1 year

Improvement of 6-minute walk distance of at least 30 meters from baseline.

6 months and 1 year
Registry Cohort: Heart Failure Hospitalization
Délai: 1 year

Comparison of the 12-month post-procedure HFH rate with the 12-month pre-procedure rate

1 year
Registry Cohort: Changes in Quality of life (by Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score).
Délai: 1 year

Change from baseline to 12 months. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL)

1 year
Roll-In Cohort: Percentage of Device- and/or Procedure-related MAEs
Délai: 1 year

Rate of Major Adverse Events

1 year
Roll-In Cohort: All-Cause mortality and Cardiovascular Mortality
Délai: 6 months and 1 year

Number of deaths from any cause as well as cardiovascular events

6 months and 1 year
Roll-In Cohort: Heart Failure Hospitalizations (HFH)
Délai: 6 months and 1 year

Number of Heart Failure Hospitalizations and worsening HF events without hospitalization

6 months and 1 year
Roll-In Cohort: RVAD Implantation or Heart Transplant
Délai: 6 months and 1 year

Number of patients requiring RVAD Implantation or Heart Transplant

6 months and 1 year
Roll-In Cohort: Atrial Fibrillation
Délai: 1 year

New onset of atrial fibrillation

1 year
Roll-In Cohort: Quality of life as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ).
Délai: 6 months and 1 year

Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life

6 months and 1 year
Roll-In Cohort: New York Heart Association (NYHA) functional class
Délai: 6 months and 1 year

Reduction of at least 1 class from baseline. NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

6 months and 1 year
Roll-In Cohort: 6-minute walk test (6MWT).
Délai: 6 months and 1 year

Improvement of 6-minute walk distance of at least 30 meters from baseline.

6 months and 1 year

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 novembre 2028

Achèvement de l'étude (Estimé)

1 novembre 2032

Dates d'inscription aux études

Première soumission

7 juin 2024

Première soumission répondant aux critères de contrôle qualité

12 juin 2024

Première publication (Réel)

14 juin 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • CTP-TRIC-005-II

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner